| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| review article | Q7318358 |
| P50 | author | Stefan Leucht | Q28036857 |
| Werner Kissling | Q28036859 | ||
| Katja Komossa | Q28050790 | ||
| Christine Rummel-Kluge | Q28050791 | ||
| P2093 | author name string | Heike Hunger | |
| Sandra Schwarz | |||
| Katja Komossa | |||
| Paranthaman Seth S Bhoopathi | |||
| P2860 | cites work | The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. | Q46672305 |
| Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial | Q46675364 | ||
| Clinical implications of Brief Psychiatric Rating Scale scores | Q46732006 | ||
| Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia | Q46732028 | ||
| Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. | Q46774609 | ||
| The CATIE schizophrenia effectiveness trial | Q46807311 | ||
| The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. | Q46811163 | ||
| A randomized double-blind comparison of ziprasidone vs. clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment. | Q46852558 | ||
| Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. | Q46983809 | ||
| Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone | Q47279555 | ||
| Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. | Q48266972 | ||
| Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. | Q50679599 | ||
| Serum prolactin levels and the acute-phase efficacy in drug-naïve schizophrenia treated with ziprasidone and olanzapine (translated version). | Q50955502 | ||
| Substance use and schizophrenia: adverse correlates in the CATIE study sample. | Q51536756 | ||
| Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia | Q21260279 | ||
| Olanzapine for schizophrenia | Q24244031 | ||
| Aripiprazole for schizophrenia | Q24246298 | ||
| Aripiprazole for schizophrenia | Q24247235 | ||
| Bias in meta-analysis detected by a simple, graphical test | Q24685585 | ||
| Measuring inconsistency in meta-analyses | Q27860655 | ||
| A rating scale for drug-induced akathisia | Q28258433 | ||
| Effectiveness of antipsychotic drugs in patients with chronic schizophrenia | Q28273164 | ||
| The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials | Q29619671 | ||
| Meta-analyses involving cross-over trials: methodological issues | Q29620304 | ||
| Imputing missing standard deviations in meta-analyses can provide accurate results | Q29620610 | ||
| Detecting skewness from summary information | Q29620977 | ||
| Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review | Q29622930 | ||
| Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia | Q30436445 | ||
| Results of phase 3 of the CATIE schizophrenia trial | Q30487308 | ||
| Extrapyramidal side-effects of antipsychotics in a randomised trial | Q30492645 | ||
| Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. | Q30573727 | ||
| Ziprasidone for schizophrenia and severe mental illness | Q30868078 | ||
| Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. | Q31005816 | ||
| Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial | Q33383396 | ||
| Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone | Q33545458 | ||
| Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia | Q33885798 | ||
| Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics | Q33993242 | ||
| Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial | Q34007868 | ||
| Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients. | Q51620290 | ||
| Antipsychotic medications do not differ substantially in ability to reduce violent behaviour in people with schizophrenia. | Q51872859 | ||
| Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. | Q51906439 | ||
| A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA). | Q53026276 | ||
| Treatment response trajectories and antipsychotic medications: examination of up to 18 months of treatment in the CATIE chronic schizophrenia trial. | Q53668053 | ||
| A rating scale for extrapyramidal side effects | Q53780342 | ||
| The Role of the Family and Improvement in Treatment Maintenance, Adherence, and Outcome for Schizophrenia | Q56781545 | ||
| Sexual Dysfunction in First-Episode Schizophrenia Patients | Q58896760 | ||
| Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: A randomized study | Q60630083 | ||
| P.3.c.054 Crossover comparison of serum glycemia variability of intramuscular forms of antipsychotics: aripiprazole, olanzapine and ziprasidone | Q60639594 | ||
| Suicide in schizophrenics, manics, depressives, and surgical controls. A comparison with general population suicide mortality | Q67261664 | ||
| The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome | Q70601646 | ||
| Schizophrenia | Q72240986 | ||
| [The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use] | Q73429086 | ||
| [Current assessment of new/atypical neuroleptic agents] | Q73878831 | ||
| The Effect of Antipsychotics on Plasma Lipids | Q79303671 | ||
| Metabolic findings from the CATIE trial and their relation to tolerability | Q79829709 | ||
| Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial | Q80428328 | ||
| Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia | Q80673050 | ||
| Different antipsychotics produce similar, small improvements in psychosocial functioning at one year in people with schizophrenia | Q81504055 | ||
| Neurocognitive effectiveness of quetiapine, olanzapine, risperidone, and ziprasidone: a pragmatic, randomized trial | Q82870181 | ||
| Selecting antipsychotics in schizophrenia: lessons from CATIE | Q83018033 | ||
| Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study | Q83136483 | ||
| A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms | Q83190501 | ||
| Second-generation antipsychotics: reviewing the cost-effectiveness component of the CATIE trial | Q84364214 | ||
| Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine | Q34048732 | ||
| SNP-based analysis of neuroactive ligand-receptor interaction pathways implicates PGE2 as a novel mediator of antipsychotic treatment response: data from the CATIE study | Q34078643 | ||
| Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data | Q34153742 | ||
| Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial | Q34480263 | ||
| Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic | Q34508750 | ||
| Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). | Q34570934 | ||
| What CATIE found: results from the schizophrenia trial | Q34591378 | ||
| Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial | Q34604314 | ||
| Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology | Q34783101 | ||
| Double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia. | Q34879022 | ||
| Issues in the meta-analysis of cluster randomized trials | Q34906716 | ||
| Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study. | Q35115704 | ||
| Analysis of efficacy and side effects in CATIE demonstrates drug response subgroups and potential for personalized medicine | Q35375788 | ||
| The unit of analysis error in studies about physicians' patient care behavior | Q35553582 | ||
| Schizophrenia and employment - a review | Q35767593 | ||
| Statistics notes. Trials randomised in clusters | Q36246100 | ||
| The long term--maximising potential for rehabilitation in patients with schizophrenia | Q36751065 | ||
| Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking | Q36828536 | ||
| Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. | Q36973177 | ||
| Clinical implications of the CATIE schizophrenia trials: day-to-day management lessons for Australasian psychiatrists | Q36999790 | ||
| Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study | Q37039179 | ||
| Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. | Q37095956 | ||
| Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia | Q37137005 | ||
| The impact of obesity on health care costs among persons with schizophrenia | Q37139663 | ||
| The association between weight change and symptom reduction in the CATIE schizophrenia trial | Q37212106 | ||
| Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. | Q37302639 | ||
| Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia | Q37315451 | ||
| A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia | Q37327871 | ||
| The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial | Q37394738 | ||
| A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial | Q37489656 | ||
| Treatment programme and long-term outcome in chronic schizophrenia | Q37604172 | ||
| Generalizability of the results of efficacy trials in first-episode schizophrenia: comparisons between subgroups of participants of the European First Episode Schizophrenia Trial (EUFEST). | Q38378189 | ||
| The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): design and baseline subject characteristics. | Q38391903 | ||
| The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone. | Q38403241 | ||
| Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST). | Q38486684 | ||
| Predicting psychiatric hospital admission among adults with schizophrenia | Q39701187 | ||
| Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial | Q40195274 | ||
| Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence | Q41682564 | ||
| Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). | Q42680500 | ||
| Effects on cognitive functioning after olanzapine–ziprasidone crossover in recent-onset schizophrenia | Q42910145 | ||
| Long-term efficacy and tolerability of clozapine combined with ziprasidone or risperidone | Q43000357 | ||
| Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis | Q43025405 | ||
| Short term neurocognitive effects of treatment with ziprasidone and olanzapine in recent onset schizophrenia | Q43056704 | ||
| Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST). | Q43142810 | ||
| Haloperidol versus chlorpromazine for treatment of schizophrenia | Q43192045 | ||
| Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial | Q43253275 | ||
| Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). | Q43264112 | ||
| Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. | Q44096389 | ||
| Treatment of depression in first episode of schizophrenia: results from EUFEST. | Q44625111 | ||
| Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder | Q44654540 | ||
| A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition | Q44717873 | ||
| Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: evidence from the CATIE study | Q44730779 | ||
| Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study | Q44863062 | ||
| Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder | Q45091260 | ||
| Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. | Q45218017 | ||
| Serological evidence of exposure to Herpes Simplex Virus type 1 is associated with cognitive deficits in the CATIE schizophrenia sample | Q45368741 | ||
| Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study. | Q45958125 | ||
| Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial. | Q45958279 | ||
| Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). | Q46049842 | ||
| Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study | Q46095947 | ||
| A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: a 44-week, double-blind, continuation study | Q46142676 | ||
| Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial | Q46358333 | ||
| Correlates of cognitive impairment in first episode schizophrenia: the EUFEST study | Q46385705 | ||
| Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial | Q46533468 | ||
| What does the PANSS mean? | Q46570213 | ||
| Methodological concerns in a trial of ziprasidone and olanzapine | Q46580915 | ||
| Relationship of cognition and psychopathology to functional impairment in schizophrenia | Q46616400 | ||
| Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia | Q46628164 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| P304 | page(s) | CD006627 | |
| P577 | publication date | 2009-01-01 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Ziprasidone versus other atypical antipsychotics for schizophrenia |
| Q24236683 | Antipsychotic medication for early episode schizophrenia |
| Q94336980 | Aripiprazole versus ziprasidone for schizophrenia |
| Q28728401 | Changes in body weight and psychotropic drugs: a systematic synthesis of the literature |
| Q36169130 | Clinical Practice Associated with a Switch from and to Ziprasidone during Routine Inpatient Treatment of Patients with Schizophrenia |
| Q43645743 | Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia |
| Q28079821 | Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive Review |
| Q35116048 | Dietary, lifestyle and pharmacogenetic factors associated with arteriole endothelial-dependent vasodilatation in schizophrenia patients treated with atypical antipsychotics (AAPs). |
| Q37060012 | Effects of ziprasidone and olanzapine on body composition and metabolic parameters: an open-label comparative pilot study |
| Q36588607 | Evidence review and clinical guidance for the use of ziprasidone in Canada |
| Q34213209 | Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis |
| Q59938422 | Les recommandations de prise en charge des complications métaboliques associées aux antipsychotiques de deuxième génération chez les enfants et les adolescents |
| Q30490054 | Long-term antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials |
| Q47587816 | Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis |
| Q35128410 | Management recommendations for metabolic complications associated with second generation antipsychotic use in children and youth. |
| Q35572645 | Management recommendations for metabolic complications associated with second-generation antipsychotic use in children and youth |
| Q33622056 | Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general population |
| Q64941915 | Movement Disorders Associated With Antipsychotic Medication in People With Schizophrenia: An Overview of Cochrane Reviews and Meta-Analysis. |
| Q36755212 | Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: the role of folate pharmacogenetics |
| Q34620095 | Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons |
| Q28651174 | Simultaneous Comparison of Efficacy and Tolerability of Second-Generation Antipsychotics in Schizophrenia: Mixed-Treatment Comparison Analysis Based on Head-to-Head Trial Data |
| Q38475985 | Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable |
| Q38473914 | Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment |
| Q36848333 | The effect of folate supplementation and genotype on cardiovascular and epigenetic measures in schizophrenia subjects. |
| Q42990103 | The effectiveness of cross-tapering switching to ziprasidone in patients with schizophrenia or schizoaffective disorder |
| Q35256929 | Treatment resistant schizophrenia: a comprehensive survey of randomised controlled trials |
| Q34357931 | Ziprasidone hydrocloride: what role in the management of schizophrenia? |
Search more.